Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
An update from Celcuity ( (CELC) ) is now available.
On May 13, 2025, Celcuity Inc. held its Annual Meeting of Stockholders where several key decisions were made. Stockholders approved an amendment to the 2017 Stock Incentive Plan, increasing the number of shares by 3,000,000, with 2,500,000 allocated for incentive stock options. Additionally, seven directors were elected, Boulay PLLP was ratified as the independent accounting firm for 2025, and executive compensation was approved.
The most recent analyst rating on (CELC) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Celcuity stock, see the CELC Stock Forecast page.
Spark’s Take on CELC Stock
According to Spark, TipRanks’ AI Analyst, CELC is a Neutral.
Celcuity’s stock score of 43.73 reflects the challenges faced by early-stage biotech firms. The company’s financial performance is weak due to lack of revenue and high expenses. Technical analysis shows a neutral to slightly negative outlook, while valuation metrics are poor due to negative earnings. Despite these challenges, the earnings call provided a positive outlook with potential future revenue and strong financial positioning. The overall score indicates significant risks but potential for future growth if clinical and financial milestones are achieved.
To see Spark’s full report on CELC stock, click here.
More about Celcuity
Average Trading Volume: 285,877
Technical Sentiment Signal: Sell
Current Market Cap: $410.9M
For detailed information about CELC stock, go to TipRanks’ Stock Analysis page.